Therapeutic Area Leader in Psychiatry, Medical and Scientific Affairs, J&J North American Pharmaceuticals

Larry Alphs received his M.D. and Ph.D. from the University of Chicago Pritzker School of Medicine with a doctorate in neuropharmacology. In addition, he completed 2 years as a PRAT fellow at NIH and a residency in psychiatry at the University of Chicago Hospitals and Clinics. He worked for 10 years in academia as a researcher/clinician specializing in clinical research with persons with serious psychiatric disorders. His interests focused on nosology and treatment of schizophrenia and drug-induced movement disorders. For the past 15 years he has worked as a clinical scientist in the pharmaceutical industry where he as done Phase I-IV work in a variety of CNS disorders, including schizophrenia, bipolar disorder, suicidality, anxiety, depression, epilepsy, neuropathic pain, and traumatic brain injury. He currently is Therapeutic Leader, Psychiatry for Ortho-McNeil Janssen in Titusville, NJ and serves as the President for the International Society for CNS Clinical Trials and Methodology.

Chief Executive Officer, Anand Pharma Consulting

Nancy U. Karren Clinical Professor, Department of Psychiatry and Professor, Department of Pharmacology, University of Texas Health Science Center at San Antonio

Dr. Bowden attended The University of Texas at Austin and earned his medical degree from Baylor College of Medicine in Houston, Texas. He completed his training in psychiatry at the New York State Psychiatric Institute and Columbia-Presbyterian Hospital in New York, New York.

Dr. Bowden was awarded the 2001 Gerald L. Klerman Senior Investigator Award by the Depression and Bipolar Support Alliance and received the 2006 Mind of America Scientific Research Award from the National Alliance for the Mentally Ill. Dr. Bowden is a Fellow of the American College of Neuropsychopharmacology and the Collegium Internationale Neuro-Psychopharmacologicum, a Corresponding Member of the European College of Neuropsychopharmacology and a member of the Executive Committee of the International Society for CNS Clinical Trials and Methodology. He is Associate Editor for Acta Psychiatrica Scandinavica and a member of the editorial boards of Bipolar Disorders and Depression and Anxiety, Dr. Bowden is a reviewer for several journals including Archives of General Psychiatry, Biological Psychiatry, and the Journal of the American Medical Association. He has authored more than 370 publications. His research is principally on the symptomatic and biological characterization of bipolar disorders and the effectiveness and pharmacodynamics of mood stabilizing drugs. He has been principal investigator for 80 studies funded by pharmaceutical companies, NIMH, and various foundations. Dr. Bowden frequently serves as consultant to pharmaceutical companies and governmental agencies and is named in Best Doctors in the US in the area of mood disorders.

Deputy Head of Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte)

Dr. Broich is professionally trained and board certified in Neurology, Psychiatry, Behavioural Psychotherapy. He completed a research fellowship at the Department of Nuclear Medicine at Hospital of the University of Pennsylvania. Dr. Broich was Vice Head in the Department of Psychiatry and Psychotherapy at the Hospital of the Martin Luther University in Halle Wittenberg. Dr. Broich held the position of Head of the Section Neurology Psychiatry at the Federal Institute for Drugs and Medical Devices (BfArM) in Bonn (Germany), and since 2005 has operated as department head for that group. He is also the German alternate member of the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMEA).

Dr. Broich is currently engaged in research in the areas of: Neuropharmacology, Neurodegenerative Disorders, Neuroimaging, Biomarkers in drug development, Clinical trial design.

Dr. Broich maintains membership in the following learned societies: German Society of Psychiatry, Psychotherapy and Neurosciences; German Society of Gerontopsychiatry; German Society of Biological Psychiatry; German Society of Neuropsychopharmacology; European College of Neuropsychopharmacology; International Psycho]geriatric Association; American Society for Experimental Neurotherapeutics (ASENT); World Federation of Biological Psychiatry.

Dr. Broich is the author and co-author of more than 90 Publications (peer reviewed articles, reviews, book sections).

Senior Director, Global Clinical Research, CNS, Merck Research

Marc Cantillon is a double board certified by American Board of Neurology and Psychiatry, Geriatric, an executive with 15 years drug development experience and Chief Medical Officer at Wellness Management LLC., a global drug development consultancy based in New Jersey. Dr. Cantillon is also advisor to Bill Gates Foundation for drug licensing and third world development. Dr. Cantillon was consulted by pharmaceutical, biotech and venture investment firms that include NPS, Impax, Praecis, Bayer, Schering, Lilly, Pfizer, Elan, Sofinnova ventures, Polaris for clinical, licensing and regulatory matters. Dr. Cantillon has expertise in translational and development in diverse therapeutic areas broadly from infectious disease, HIV and osteoporosis but core expertise in the central nervous system area mainly anesthesiology, analgesia, neurology, and psychiatry. Dr. Cantillon has extensive U.S. and global clinical trial experience. Dr. Cantillon has also held position at Wyeth Pharmaceuticals, Synthelabo Pharmaceuticals (merged with Sanofi) and Astra-Zeneca Pharmaceuticals. He helped Seroquel®, Effexor® development and their global registration in the blockbuster category.

Dr. Cantillon has co-produced two educational video films/documentaries related to psychiatric illness with APA group which won Emmy Award, National Academy of Television Arts and Sciences plus second prize, American Film and Video Festival, Chicago, both for "Through Madness" documentary on psychosis in 1992. Dr. Cantillon is an author/coauthor of 24 research articles published in the peer reviewed journals and two books.

Senior Vice President, Chief Medical Officer, United BioSource Corporation

David G. Daniel, M.D. is Senior Vice President, Chief Medical Director and Practice Leader, United BioSource Corporation and Clinical Professor of Psychiatry and Behavioral Sciences, George Washington University. He was the founder of Bioniche Development Inc. and Global Learning, LLC and a founder and former principal of Best Practice, LLC. He served as Director of Clinical Trials for the Stanley Medical Research Institute. Dr. Daniel has received patent protection in the United States for processes for treatment of epilepsy, panic disorder and acute dystonic reactions.

Dr. Daniel graduated Phi Beta Kappa and Magna Cum Laude from Emory University. He received his medical education and residency training at Vanderbilt University where he served as Chief Resident and received the Marc Hollender Award. He was a senior staff fellow within the intramural program of the NIMH and served as Medical Director of the NIMH Neuroscience Center at Saint Elisabeths where he supervised all clinical research.

Professor of Psychiatry, Department of Psychiatry, Sheba Medical Center, Israel

Michael Davidson, MD is a graduate of the State University of Milan Medical School (1976). He trained in cardiology and medicine (Tel Aviv Medical Center) and psychiatry (Metropolitan Hospital and Mount Sinai School of Medicine, NY) between 1976 and 1984, and was Unit Director, Division Director in Old Age Psychiatry at Mount Sinai, and Associate Clinical Director, Pilgrim Psychiatric Hospital (NY), before moving to the Psychiatric Services and Memory Clinic, Sheba Medical Center (Israel) in 1995. Currently he is Director of the department of psychiatry at the Chaim Sheba Medical Center, Tel Aviv, he is Board Certified in Psychiatry in Israel and the United States.

Dr. Davidson’s early work focused on the development of clinical methodologies to measure amine concentrations, which was believed to reflect central DA activity and hence could help understand psychosis. When developments in molecular biology brought the direct examination of the brain tissue to the fore in psychiatric research, he saw that a brain bank with ante-mortem phenomenological assessment was needed. He established what is now the largest brain bank with ante-mortem assessment, from which researchers around the world may obtain tissue and, possibly, correlate their biological findings with detailed clinical phenomenological data. He has also described schizophrenia in old age and demonstrated that, for the most part, psychotic symptoms do not burn out as previously believed, and cognitive impairment is the major determinant of these patients’ symptoms and level of functioning. As a corollary to this work, he investigated the process of institutionalization and de-institutionalization, and other social aspects of the illness.

His focus, in investigating dementia, particularly Alzheimer’s disease, was to show that manipulation of the cholinergic activity might benefit AD patients. Aware that Ache is only one of several neurotransmitters deficient in AD, he took part in studies combining cholinergic and adrenergic augmenting drugs in AD, such as clonidine and yohimbine, as well as non-specific augmentation, such as aminopyridine. He also investigated if non-pharmacological strategies might help delay cognitive decline in the elderly and demonstrated that non-specific intellectual activity has a mild effect in this direction. Currently he is involved in investigating the role of cardiovascular risk factors in dementia. His latest publication in the field is Beeri M, Goldbourt U, Silverman JM, Noy S, Schmeidler J, Ravona R, Sverdlick A, Davidson M “Diabetes mellitus in midlife and the risk of dementia three decades later”, Neurology 63: 1902-1907 2004 

He is the recipient of many awards and grants, has published or edited more than 200 scientific articles and/or books. He co-chaired IPA’s Jerusalem Congress (1997) and was elected to the Board of Directors in 2000. Other professional affiliations include ACNP, ECNP, the World Psychiatric Association, Section on Biological Psychiatry. He is a reviewer for NIMH, and the Israeli Chief Scientist Committee and for journals such as AJP, Arch Gen Psychiatry to Alzheimer’s disease and Associated Disorders to name only a few. He has recently received the prestigious ECNP Neuropharmacology award. Over the last 2 years he has been the chair of the IPA publication committee.  He has served on IPA’s Board of Directors since 2000.

Director, Division of Health Services Research, University of Maryland School of Medicine

Dr. Dixon received a Bachelor’s Degree in Economics at Harvard College. She then completed her Medical Degree at the Cornell University Medical College, a research fellowship at the Maryland Psychiatric Research Center, and a Masters of Public Health at the Johns Hopkins School of Hygiene and Public Health. Dr. Dixon joined the faculty of the University of Maryland School of Medicine in 1990, serving as the Medical Director of the Assertive Community Treatment Team for Homeless Mentally Ill Adults. She became Director of Education and Residency Training in 1998, a position she held until 2002. Dr. Dixon joined the VA as Associate Director of Research for the Mental Illness Research, Education and Clinical Center in 2001 and assumed the additional role of Director of the Division of Services Research in 2002.

Dr. Dixon’s clinical experience and research have focused on persons with severe mental illnesses such as schizophrenia who have co-morbid medical and substance use disorders, homelessness and other vulnerabilities as well as on services to family members. The overall goal of her work has been to develop, test and disseminate strategies to improve the quality of care for persons with these disorders. She has received competitive grant funding from NIMH, NIDA, the VA and private foundations. She has received numerous local and national awards, chairs the NIMH health services specialty sector review committee, and has authored more than 100 papers published in peer-reviewed journals.

Rosalynn Carter Chair in Mental Health, Emory University, Georgia

As the first Rosalynn Carter Chair in Mental Health at Emory University, Dr. Druss is working to build linkages between mental health and broader public health and health policy communities. Dr. Druss has published more than 100 peer-reviewed articles largely focusing on the policy and systems issues on the interface between primary care and mental health.  He has received several national awards for his work, including the 2000 American Psychiatric Association Early Career Health Services Research Award, the 2000 AcademyHealth Article-of-the-Year Award, and the AcademyHealth 2003 Alice S. Hersh New Investigator Award.  In 2006, was the recipient of a five-year Career Award from the National Institute of Mental Health titled “Mending the Public Safety Net: Improving Linkages Between CHCs and CMHCs.”

Scientific Affairs, J&J North American Pharmaceuticals

Margaret T. Morris Professor of Health Economics, Department of Health Care Policy, Harvard Medical School

Dr. Frank is engaged in research in three general areas: the economics of mental health care, the economics of the pharmaceutical industry, and the organization and financing of physician group practices.

Dr. Frank and his colleagues are examining competing strategies for organizing and financing mental health and substance abuse care under research grants from the Hogg Foundation, the Robert Wood Johnson Foundation, and the National Institute of Drug Abuse. Under grants from NIDA and the MacArthur Foundation, Dr. Frank and colleagues are studying the performance of social insurance programs for people with mental and addictive disorders.

Dr. Frank’s work in the area of pharmaceuticals has focused on drug pricing and the dynamics of competition. He has also conducted studies on the impact of prescription drug formularies and the economics of new psychotropic drugs.

The third area of activity involves understanding the economic and organizational factors that influence the performance of medical group practices. Dr. Frank and his colleagues are studying the organizational, managerial, and financial factors that explain variation in the performance of medical group practices.

Dr. Frank served on the Congressional Citizen’s Working Group on Health Care. He advises several state mental health and substance abuse agencies on issues related to managed care and financing of care. In 1997 Dr. Frank was elected to the Institute of Medicine. He was awarded the Georgescu-Roegen prize from the Southern Economic Association for work on drug pricing, the Carl A. Taube Award from the American Public Health Association, and the Emily Mumford Medal from Columbia University’s Department of Psychiatry. In 2002 Dr. Frank received the John Eisberg Mentorship Award from National Research Service Awards. He received a BA in economics from Bard College and a PhD in economics from Boston University.

Global Head Neuroscience, F. Hoffmann LaRoche

George Garibaldi, M.D. is Global Head of Neuroscience and Clinical Development for F. Hoffmann La Roche. As well as serving now as Past President of the ISCTM, Dr. Garibaldi serves on the Executive Committees for the International College for Geriatric Psychoneuropharmacology (ICGP), the American Academy of Child and Adolescent Psychiatry (AACAP), and the Collegium Internationale Neuropsychopharmacologicum.

Professor, Psychiatry, The Mount Sinai School of Medicine

Dr. Haroutunian came to Mount Sinai after completing a postdoctoral training program at Princeton concentrating on research in development and in aging. His research interests since joining the Mount Sinai faculty have centered on the neurobiology of Alzheimer's disease and schizophrenia. He directs the Division of Basic and Laboratory Science in the Department of Psychiatry, the Alzheimer's disease and Schizophrenia Brain Bank, a National Institute of Aging program project grant entitled Clinical and Biological Studies of Early Alzheimer's disease, a National Institute of Mental Health R01 grant and a Veterans Affairs Merit grant on the roles of glutamate in schizophrenia, and is the Associate Director for Research for the Veterans Administration Mental Illness Research and Education Clinical Center. He is also a major contributor to Mount Sinai's Silvio Conte Center for Neuroscience and the Alzheimer's disease Research Center. In the past decade Dr. Haroutunian's research has centered on clinical and neuropathological correlated of schizophrenia and dementia. He has used molecular biological techniques, including microarray technology (DNA-chip) and neuropathological studies to understand the biological substrates of mental illness and dementia. Dr. Haroutunian works closely with his associates and colleagues Dr. Stella Dracheva and Dr. Pavel Katsel and collaborates with many members of the Department of Psychiatry and researchers at Mount Sinai and multiple other institutions in the US and around the world. These collaborations include studies conducted jointly with Dr. Kenneth Davis, Dr. Joseph Buxbaum, Dr. Giulio Pasinetti, Dr. Gregory Elder and Dr. Philip Harvey.

Professor of Psychiatry at Emory University School of Medicine

Dr. Harvey was formerly professor of Psychiatry at Mt. Sinai School of Medicine and Chief Psychologist at Mt. Sinai Hospital. He received his PhD in Clinical Psychology from SUNY at Stony Brook in 1982.  He is the author of over 700 scientific papers and abstracts and he has written over 30 book chapters.  He has given more than 1,300 presentations at scientific conferences and medical education events.  He has edited 5 books and written 4 books on topics of psychological assessment, schizophrenia, and aging.  He is a member of the American Psychological Association, the American College of Neuropsychopharmacology, the Collegium Internationale Neuropharmacologium (Fellow) , the Society for Research in Psychopathology (Founding Member), International College of Geriatric Psychoneuropharmacology (Founding Member), the Society for Biological Psychiatry, International Neuropsychological Society,  the Schizophrenia International Research Society (Founding Director), and the International Society for Clinical Trials and Methodology (Founding Member)..

His research has focused for years on cognition and he has written extensively on aging in schizophrenia, functional impairments in the illness, the cognitive effects of typical and atypical antipsychotics, as well as studying the effects of cognitive enhancing agents in various conditions, including schizophrenia, dementia, and traumatic brain injury. He directs a large and successful biennial conference on cognition that is an official satellite of the International Congress on Schizophrenia Research.  The last two meetings of this conference were attended by more than 450 scientists from around the world and this meeting was also an official satellite of the Schizophrenia Winter Workshop. 

He is also active in clinical work and teaching, performing over 1,000 psychological assessments and teaching and supervising undergraduate, predoctoral, and  postdoctoral psychology students and medical students, residents, and fellows for the past 25 years.

Acting Director, Division of Services and Intervention Research, National Institute of Mental Health

After obtaining the doctoral degree in clinical psychology from Catholic University, Dr. Heinssen worked for 12 years at Chestnut Lodge Hospital, where he developed and directed several science-based, multi-disciplinary treatment programs for schizophrenia in inpatient, partial hospital, residential, and community outpatient settings. He is the founder and past president of the Schizophrenia Special Interest Group within the Association for Advancement of Behavior Therapy and currently serves on the American Psychological Association’s Task Force for Serious Mental Illness. Dr. Heinssen is on the Editorial Board of Clinical Psychology Review and serves as an editorial consultant for several other scientific journals.

Director of Financial and Information Services, MCPP Healthcare Consulting, Inc.

Dale Jarvis, CPA, Director of Financial and Information Services for MCPP Healthcare Consulting, brings a diverse background as administrator, author and educator to healthcare organizations throughout the western United States. Prior to forming MCPP Healthcare Consulting, Dale was a principal and head of the Consulting Services Department for Jacobson Jarvis & Co., PC, a CPA firm. He has served as the financial director and accounting supervisor for healthcare organizations in Washington and Michigan. He also taught Health Care Financial Management at the University of Washington School of Public Health.

Dale is a co-author of How to Thrive in Managed Behavioral Healthcare: A workbook guide to organizational and clinical quality and The Primary Care Performance Management System: A Team Approach to Winning in the New Healthcare Market, both published by Manisses Communications. Dale's work focuses on:

• Financial and Information System Design, Procurement and Implementation
• Software Modeling to Test Clinical Designs for Financial Feasibility
• Clinician and Management Reporting System Design and Development
• Infrastructure Development for Healthcare Payors and Providers

Vice President, Medical and Scientific Services, and Global Therapeutic Team Leader CNS, Quintiles Inc.

As Vice President, Medical and Scientific Services, and Global Therapeutic Team Leader CNS, at Quintiles Inc., Dr. Kalali is currently focusing on developing novel compounds for the treatment of disorders of the central nervous system. He is globally responsible for the medical and scientific aspects of development programs in psychiatry and neurology. He is also Professor of Psychiatry at University of California San Diego

He was the Founding Chairman of the Executive Committee of the International Society for CNS Drug Development (ISCDD), and currently the Executive Secretary. Dr. Kalali is also Chair of the Membership Committee of the International Society for CNS Clinical Trials and Methodology (ISCTM), as well as a member of the Scientific Committee. In these roles he is active in facilitating scientific collaboration between academia, government, and pharmaceutical industry scientists.

Dr. Kalali received his M.D. from the University of London, United Kingdom. He completed his psychiatry training at University College and Middlesex School of Medicine, London University. He was then appointed to a clinical research faculty position at the University of California Irvine, where he also held several positions including Director of the Mood and Anxiety Disorders Clinical Research Program, and the Director of the Consultation Liaison Psychiatry Program at the Clinical Cancer Research Center.
He was also involved as an investigator on several NIH Center research programs, including the Center for Neuropathological and Genetic Abnormalities in Depression, and the Center for Neuroscience and Schizophrenia, investigating Neurobiological Brain Abnormalities in Schizophrenia.

Dr. Kalali has been an academic investigator in over 70 psychopharmacological clinical trials and at Quintiles has had medical and scientific responsibility for over 200 clinical trials.
He is an expert in CNS clinical trial methodology, including clinical rating scales, and has trained investigators from over forty countries.

Dr. Kalali is the Editor of the journal Psychiatry, and is on the editorial board of several other journals. He has published widely in journals such as the Archives of General Psychiatry, The American Journal of Psychiatry, and the British Journal of Psychiatry.

Dr. Kalali regularly presents at national and international scientific meetings, and lectures frequently on psychopharmacological and drug development topics. He is particularly interested in educating clinicians worldwide, and is facilitating this currently by being the Chairman of the Educational Committee of the Collegium Internationale Neuro-Psychopharmacologicum (CINP).

Dr. Kalali is an active member of the Scientific Advisory Boards of many pharmaceutical companies and sits on the Board of Directors of Cypress Bioscience.

In 2005, 2006 and 2008 PharmaVOICE magazine named Dr. Kalali as one its 100 most inspiring leaders in the life sciences

Dr. Kalali is an active member of many professional societies including the American College of Neuropsychopharmacology, the American Society for Clinical Psychopharmacology, the American Psychiatric Association, the Canadian College of NeuroPsychopharmacology, the Collegium Internationale Neuro Psychopharmacologicum, the Drug Information Association, the International Society for CNS Drug Development, the International Society for CNS Clinical Trials and Methodology, the Royal College of Psychiatrists, United Kingdom, and the Society for Neuroscience.

Professor, Departments of Psychiatry and Behavioral Sciences and Psychology, Duke University Medical Center; President of Neurocog Trials, Inc.

Dr. Keefe's research is primarily devoted to understanding cognitive dysfunction in patients with schizophrenia and related disorders, including those at high risk for schizophrenia. He has a specific interest in the treatment of cognitive deficits in schizophrenia and designing methods to assess cognitive change.

Dr. Keefe has led the development of the battery of tests for several multi-site studies of cognitive dysfunction treatment-response, including the National Institute of Mental Health (NIMH) Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the Brief Assessment of Cognition in Schizophrenia (BACS), a battery of tests that can be used in clinical trials or clinical settings to assess cognitive deficit treatment response. He is a member of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Neurocognition Committee and Director of the Chief Neuropsychologists for the NIMH Treatment Units for Research on Neurocognition and Schizophrenia (TURNS) project, which aims to find new medications for improving cognition in patients with schizophrenia.

In addition to more than 120 scientific papers on schizophrenia, Dr. Keefe has authored Understanding Schizophrenia (1994) and On the Sweet Spot: Stalking the Effortless Present (2003). He has also edited two books, The Assessment of Negative Symptom and Cognitive Deficit Treatment Response (2000) and Improving Cognitive Function in Schizophrenia, 2nd ed. (2004). He serves on the Editorial Boards of Schizophrenia Research, Schizophrenia Bulletin, and Psychiatry. He is on the Scientific Board of NARSAD.

Dr. Keefe received his BA from Princeton University and his Ph.D. in clinical psychology from New York University..

Division Director, Division of Psychiatry Products, Center for Drug Evaluation and Research, FDA

Dr. Laughren is currently Division Director for the Division of Psychiatry Products, Center for Drug Evaluation and Research at FDA. Prior to coming to FDA in September, 1983, Dr. Laughren was affiliated with the VA Medical Center in Providence, RI, and was on the faculty of the Brown University Program in Medicine. He received his medical degree from the University of Wisconsin in Madison, Wisconsin, and he also completed residency training in psychiatry at the University of Wisconsin. Dr. Laughren is board certified in general psychiatry.

As Division Director for the Division of Psychiatry Products, Dr. Laughren oversees the review of all psychiatric drug development activities conducted under INDs and the review of all NDAs and supplements for new psychiatric drug claims. He has authored and co-authored many papers on regulatory and methodological issues pertaining to the development of psychiatric drugs, and is a frequent speaker at professional meetings on these same topics. Dr. Laughren has received numerous awards from FDA for his regulatory accomplishments.

Director, Quantitative Safety Research, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Bennett Levitan, MD-PhD is Director, Quantitative Safety Research at Johnson & Johnson Pharmaceutical Research and Development.  Dr. Levitan has over 20 years experience in modeling and simulation in both consulting and pharmaceuticals.  He specializes in pharmaceutical benefit-risk assessment and applications of machine learning in pharmaceutical development, and is currently leading technical development of the PhRMA Benefit Risk Action Team (BRAT) Framework for drug benefit-risk assessment.  Bennett received his B.Sc. (Electrical Engineering) from Columbia University in New York and his M.D.-Ph.D. (Bioengineering) from the University of Pennsylvania.  He worked as a postdoctoral fellow at the Santa Fe Institute.  His research and consulting work have dealt with pharmaceutical benefit-risk assessment, organizational learning, evolutionary-based optimization, high-dimensional data visualization, and combinatorial chemistry.

Senior Vice President, Science Policy, United Biosource Corporation

Dr. Luce founded MEDTAP® International (merged with UBC in 2004), serving as its Chairman, President and CEO until 2002. Previously, he held positions as Director of Battelle’s Centers for Public Health Research and Evaluation, Director of the Office of Research and Demonstrations, Centers for Medicare and Medicaid Services and Senior Analyst, Office of Technology Assessment (OTA) of the United States Congress.
He is also a consultant to numerous government agencies as well as pharmaceutical and device firms worldwide, chairs or serves on socioeconomic and public health policy advisory boards for several leading pharmaceutical companies, and recently was a member of the Medicare Evidence Development & Coverage Advisory Committee (MedCAC).

Dr. Luce holds academic appointments as Senior Scholar with the Department of Health Policy, Jefferson Medical College and Adjunct Senior Fellow of the Leonard Davis Institute, University of Pennsylvania. Author of more than eighty scientific publications, including three textbooks on technology assessment, health policy, and cost-effectiveness analysis, he is on the editorial boards of several leading health journals.
A past president of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), he founded and chairs the Bayesian Initiative in Health Economics and Outcomes Research.

Dr. Luce’s undergraduate and masters training were at the Universities of Vermont and Massachusetts at Amherst. He received his Doctorate from the School of Public Health at the University of California at Los Angeles (UCLA).

Director of Mental Health and Substance Use Programs, Global Health Sector, SRA International

Ronald W. Manderscheid, Ph.D., has served as the Director of Mental Health and Substance Use Programs at the Global Health Sector of SRA International since 2006. In this capacity, he is developing new demonstration and research projects around mental health and substance use services, programs, and systems, using a public health framework. Areas of focus include transformation of financing, human resources, evidence-based practices, information technology, statistical data, performance measures, and quality report cards. Consumer and family concerns pervade all of this work. Concurrently, he is Adjunct Professor at the Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, and a Member of the Secretary of Health and Human Services Advisory Committee on Healthy People 2020. Dr. Manderscheid serves on the boards of the Employee Assistance Research Foundation, the American College of Mental Health Administration, the Danya Institute, and the Public Manager. Previously, Dr. Manderscheid served as Branch Chief, Survey and Analysis Branch, for the federal Center for Mental Health Services (CMHS), SAMHSA.

Dr. Manderscheid is currently on the Governing Council of the American Public Health Association (APHA), current President of the Federal Executive Institute Alumni Association (FEIAA) Foundation, Past President of FEIAA, and past Chair of the APHA Mental Health Section. He has also served as the Chairperson of the Sociological Practice Section of the American Sociological Association, and as President of the Washington Academy of Sciences and the District of Columbia Sociological Society.

During the Clinton National Health Care Reform debate, Dr. Manderscheid served as Senior Policy Advisor on National Health Care Reform in the Office of the Assistant Secretary for Health at the U.S. Department of Health and Human Services. At that time, Dr. Manderscheid was also a member of the Mental Health and Substance Abuse Work Group of the President's Task Force on Health Care Reform.

Dr. Manderscheid served as principal editor for eight editions of Mental Health, United States. He has also authored numerous scientific and professional publications on services to persons with mental illnesses. Each month, he prepares the Manderscheid Report for Behavioral Healthcare.

Dr. Manderscheid is the recipient of both federal and professional awards, including the 1995 National Sociological Practice Award; Substance Abuse and Mental Health Services Administration (SAMHSA) Administrator's Award for Meritorious Achievement, 1995; SAMHSA Administrator's Award for Meritorious Achievement (Group Award to Branch) 1995; 1st Annual Going to Bat Award, National Association for Rural Mental Health, 1996; Friends of Case Management Award, National Association of Case Management, 1996; Quality of Work Life SAMHSA Partnership Award, 1997; SAMHSA Outstanding Teamwork Award, 1997; Loras College Distinguished Alumni Award, 1998; Federal Executive Institute Alumni Association's Meritorious Service Award, 1999; HHS Secretary's Distinguished Service Award, 1999, 2004, 2005, 2006, and 2008; American Public Health Association's Mental Health Section Award, 2000; Mental Health Statistics Improvement Program's National Leadership Award, 2001; American Association for Psychosocial Rehabilitation's Irving T. Blumberg Humanitarian Award, 2002; American College of Mental Health Administration's Saul Feldman Lifetime Achievement Award, 2003, and Distinguished Service Award, 2006; National Association of State Mental Health Program Directors Career Distinguished Service Award, 2006; National Council of Community Behavioral Healthcare Distinguished Public Service Award, 2006; and 50th Anniversary Award, Southern Regional Conference on Mental Health Statistics, 2008.

Dr. Manderscheid worked in a variety of positions with the National Institute of Mental Health (NIMH). While there, he served as NIMH's Chief, Statistical Research Branch, where he provided strong leadership in implementing the National Reporting System (NRP) and the Mental Health Statistics Improvement Program (MHSIP).

Dr. Manderscheid received a B.A. degree (with highest honors) in Sociology from Loras College; a M.A. degree in Sociology-Anthropology from Marquette University; and a Ph.D. in Sociology, with a specialization in Social Psychology and Statistics from the University of Maryland. He is also a graduate of the Federal Executive Institute.

Director of the Department of Veterans Affairs VISN 22 Mental Illness Research, Education, and Clinical Center, Director of the Section on Psychosis of the Semel Institute for Neuroscience and Human Behavior at UCLA, Professor of Psychiatry at the David Geffen School of Medicine at UCLA.

Dr. Marder's research has focused on improving the long-term treatment of individuals with schizophrenia through pharmacological and psychosocial strategies. He was the Principal Investigator for the NIMH MATRICS initiative to improve neurocognition in schizophrenia as well as the leader of a trials network to study candidate drugs for enhancing cognition.

Dr. Marder has received the Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill, the Stanley Dean Research Award of the American College of Psychiatry, the Alexander Gralnick Award for Schizophrenia Research from the American Psychiatric Association, and the APIRE/Kempf Fund Award for Research Development is Psychobiological Psychiatry He is listed in The Best Doctors in America and America's Top Doctors.

Director, Trent Center for Bioethics, Humanities & History of Medicine
Professor of Pediatric Infectious Diseases, Duke University

Ross McKinney, Jr, MD is a Professor of Pediatrics and Professor of Molecular Genetics and Microbiology. He is a pediatric infectious diseases specialist who graduated from Dartmouth College in 1975, the University of Rochester School of Medicine and Dentistry in 1979, and arrived at Duke for his internship and residency in Pediatrics. He continued at Duke for a fellowship in Pediatric Infectious Disease with Drs. Cathy Wilfert, Laura Gutman, and Samuel Katz. He joined the Duke faculty in 1985. His initial research was on the pathogenesis of enteroviral infections in patients with X-linked agammaglobulinemia. He switched areas of focus in 1987, moving to pediatric HIV clinical research. Dr. McKinney was first author of the key Phase I and II papers regarding Zidovudine (AZT) use in children. Dr. McKinney continues to do research regarding the natural history, prevention, and treatment of pediatric HIV disease. He served as director of the Division of Pediatric Infectious Diseases from 1994-2003. Dr. McKinney served two terms as Chairman of the Sub-board for Infectious Diseases of the American Board of Pediatrics (1998-2001). In 2002, he was appointed Vice Dean for Research for the Duke University School of Medicine, and served until 2007, when he became the Director of the Trent Center for Bioethics, Humanities & History of Medicine. His areas of research focus are conflict of interest and the process of informed consent. He is the chair of the Steering Committee for the Forum on Conflict of Interest in Academe for the American Association of Medical Colleges.

Deputy Director, Division of Drug Risk Evaluation, Food and Drug Administration

Dr. Ann W. McMahon received a Masters of Science in Health Policy and Management from the Harvard School of Public Health in 1983, and went on to receive an MD from the Case Western Reserve University School of Medicine in 1987. She completed her residency in Pediatrics at the Johns Hopkins Children’s Center in 1990, and continued with post-doctural training both at the National Institutes of Health and Johns Hopkins Children’s Center in Virology and Pediatric Infectious Diseases. After an Assistant Professorship at the University of Chicago, she joined the Food and Drug Administration in 2002. Since joining the FDA, she has focused on post-marketing safety; the first 5 years of her tenure primarily on vaccine safety, and the last 3 years primarily on the safety of drugs and biologics. She currently holds the title of Deputy Director, Division of Pharmacovigilance I, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research.

Associate Professor, Department of Medicine and Associate Faculty Member, Harris School and the Department of Economics, University of Chicago

David Meltzer is Associate Professor in the Department of Medicine, Department of Economics, and Harris School of Public Policy Studies and Director of the Center for Health and the Social Sciences (CHeSS) at the University of Chicago. He is also co-director of the Robert Wood Johnson Clinical Scholars Program, the MD/PhD Program in the Social Sciences at the University of Chicago, and he directs the CDC-funded Chicago Center of Excellence in Health Promotion Economics. He is also on the faculty of the graduate program in Health Administration and Policy, the Population Research Center and the Center on Aging. Meltzer’s research explores problems in health economics and public policy. Among his areas of study are the theoretical foundations of medical cost-effectiveness analysis, including issues such as accounting for future costs due to the extension of life and the empirical validity of quality of life assessment, which he has examined in the context of diabetes and prostate cancer, and determinants of the cost and quality of hospital care. Meltzer is principal investigator in a randomized trial examining the use of in-hospital physicians versus traditional physicians in six academic medical centers. Other work examines the effects of prospective payment systems on the cost and quality of care, and the effects of FDA regulation on innovation in the pharmaceutical industry. Meltzer, who did his residency in internal medicine at Brigham and Women's Hospital in Boston, earned his M.D. and Ph.D. in economics at the University of Chicago.

Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology, Washington University School of Medicine

John C. Morris, MD, is the Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology; Professor of Pathology and Immunology; Professor of Physical Therapy; Professor of Occupational Therapy; and Director of the Alzheimer's Disease Research Center, Memory and Aging Project at Washington University School of Medicine. He is also Director of the Center for Aging at Washington University.

Dr. Morris earned his medical degree from the University of Rochester School of Medicine and Dentistry in Rochester, New York. He completed a residency in neurology at the Cleveland Metropolitan General Hospital in Ohio and a postdoctoral fellowship in neuropharmacology at Washington University School of Medicine.

Research interests of Dr. Morris include healthy aging and senile dementia, antecedent biomarkers for Alzheimer’s disease, genetic associations with Alzheimer-free survival, and PET amyloid imaging in nondemented elderly to evaluate Alzheimer risk.

Dr. Morris is the former editor-in-chief of the journal, Alzheimer's Disease and Associated Disorders: an International Journal. He has authored or coauthored 4 books and more than 300 published articles, abstracts, and book chapters. Dr. Morris is a member of several professional societies including the American Academy of Neurology and the American Neurological Association. He serves on scientific and community advisory boards, including the Medical and Scientific Advisory Council of the national Alzheimer’s Association and the National Advisory Council on Aging for the National Institute on Aging. He has received many honors and awards, including the Lifetime Achievement Award from the Alzheimer’s Association (2004); the MetLife Award for Medical Research in Alzheimer’s Disease (2004); and the Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Dementias from the American Academy of Neurology (2005); Physician-Scientist Lifetime Achievement Award, Barnes-Jewish Hospital Foundation, St. Louis, MO (2005); Neville Grant Award for Clinical Excellence from Barnes-Jewish Hospital, St. Louis, MO (2006); ISI Highly Cited Investigator (2007); Washington University Academic Women’s Network Mentor Award (2008).

Medical Director Psychiatric Services, Missouri Department of Mental Health

Dr. Parks serves as the Chief Clinical Officer for the Department of Mental Health as well as the Director for the Division of Comprehensive Psychiatric Services for the State of Missouri Department of Mental Health in Jefferson City.   He also serves as a Clinical Assistant Professor of Psychiatry at the Missouri Institute of Mental Health and University of Missouri in Columbia. He serves as President of the Medical Director’s Council of the National Association of State Mental Health Program Directors.  He practices psychiatry on an outpatient basis at Family Health Center, a federally funded community health center established to expand services to uninsured and underinsured patients in the Columbia area.

Dr. Parks has authored or coauthored a number of original articles, monographs, technical papers, and reviews on implementation of Evidence Based Medicine and Pharmacy Utilization Management and behavioral treatment programs. His work has appeared in several journals (Journal of Organizational Behavior, Journal of Psychiatric Practices, Psychiatry Quarterly, Manual of Clinical Emergency Psychiatry, Behavioral Interviews, Hospital and Community Psychiatry, and Advanced Studies in Nursing.

He was awarded the 2006 American Psychiatric Association Bronze Achievement Award for a program controlling pharmacy costs by improving prescribing practices.

Chairman, National Institute for Health and Clinical Excellence (NICE)

Sir Michael Rawlins has been chairman of the National Institute of Health & Clinical Excellence (NICE) since its formation in 1999. He is also an Honorary Professor at the London School of Hygiene and Tropical Medicine, University of London, and Emeritus Professor at the University of Newcastle upon Tyne.

He was the Ruth and Lionel Jacobson Professor of Clinical Pharmacology at the University of Newcastle upon Tyne from 1973 to 2006 .At the same time he held the position of consultant physician and consultant clinical pharmacologist to the Newcastle Hospitals NHS Trust. He was vice-chairman (1987-1992) and chairman (1993-1998) of the Committee on Safety of Medicines; and chairman of the Advisory Council on the Misuse of Drugs (1998 - 2008).

President and CEO, Mental Health America

Dr. Shern was named in 2006 as the president and CEO of Mental Health America then names the National Mental Health Association. MHA is the country's oldest and largest nonprofit organization addressing all aspects of mental health and mental illness. Prior to joining MHA, Dr. Shern served as dean of the Louis de la Parte Florida Mental Health Institute (FMHI) at the University of South Florida, one of the largest research and training institutes in behavioral health services in the United States. He also founded and directed the National Center for the Study of Issues in Public Mental Health - a National Institute of Mental Health-funded services research center located in the New York State Office of Mental Heath (OMH).

His work has spanned a variety of mental health services research topics including epidemiological studies of the need for community services; the effects of differing organizational, financing and service delivery strategies on continuity of care and client outcome and the use of alternative service delivery strategies such as peer counseling and self help on the outcomes of care. He has authored more than 100 publications including papers in Health Affairs, Psychiatric Services, Medical Care, Health Services Research, Behavioral Health Services and Research and the American Journal of Public Health.

In 2008, Dr. Shern received the prestigious Luminary Award from the National Alliance for Research on Schizophrenia and Depression (NARSAD), for his outstanding contributions to mental health research. In addition, he received the 2006 Carl Taube award from the American Public Health Association in recognition of his career contributions to mental health services research. Recently, he received a Presidential Citation for outstanding service from the American Psychological Association.

In 2000, Governor Jeb Bush appointed Dr. Shern to the Florida Commission on Mental Health and Substance Abuse. He was elected Chair of the Commission by his fellow Commissioners and spearheaded an effort to develop a new statewide focus on and governance model for behavioral health across all human service agencies and settings.

Dr. Shern not only has an extensive research background but is an advocate committed to represent the interest of mental health consumers. He serves on the board of the Campaign for Mental Health Reform and on the National Advisory Committee for the Agency for Healthcare Research and Quality. He has testified before the U.S. Congress on the inclusion of behavioral health in all aspects of healthcare reform.

Executive Director, Clinical Disease Area Expert, Alzheimer's Disease, Pfizer Inc.

Dr. Schindler is a board certified neurologist, with subspecialty training in Neuropsychiatry and Behavioral Neurology. She received her B.A. from the University of Pennsylvania and her M.D. from the Albert Einstein College of Medicine. She trained in Internal Medicine and Neurology at the Mount Sinai School of Medicine and completed a fellowship in Neuropsychiatry and Behavioral Neurology at Beth Israel Medical Center in New York City.

She was Director of Behavioral Neurology and Neuropsychiatry, Chief of Neurorehabilitation, and Assistant Professor of Neurology at the State University of New York at Stony Brook.  There, she founded and directed The Neurobehavior and Memory Disorders Program, a comprehensive multidisciplinary program serving patients and their families with neurobehavioral and memory disorders related to Alzheimer’s disease and other dementias, head injury, stroke, epilepsy, and other neurological disorders. 

She was a principal investigator on numerous clinical trials in Alzheimer’s disease, including with the Alzheimer’s Disease Cooperative Study (ADCS), the part of the NIA Neuroscience and Neuropsychology of Aging Program's effort to facilitate the discovery, development and testing of new drugs for the treatment of AD.  She was also an attending neurologist at University Hospital at Stony Brook, the Northport VA Medical Center, the Gurwin Jewish Geriatric Nursing Center, a consultant at St. Charles Rehabilitation Hospital, and led a multidisciplinary team at the St. Johnland Head Injury Rehabilitation Unit. 

She established a post-graduate fellowship training program in neurobehavioral and cognitive disorders, and also taught and supervised residents and medical students, graduate and undergraduate students.  She has taught courses on Alzheimer’s disease at the American Academy of Neurology.  Both before and since joining Pfizer in 2000, she has focused on cognitive and behavioral disorders in Neurological and Psychiatric conditions, most notably Alzheimer’s disease.

Since joining Pfizer, she has worked in both Clinical Development and Medical in Alzheimer’s disease, and is currently the company’s Clinical Disease Area Expert in Alzheimer’s disease.  She has participated in various US and global initiatives and consensus groups to advance research and the care of Alzheimer’s patients, including the Alzheimer’s Association Research Roundtable, the European Alzheimer’s Disease Consortium, the Industry Scientific Advisory Board for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and has represented the European Federation of Pharmaceutical Industries and Associations (EFPIA) at the EMEA on recommendations on guidelines on treatment in dementia.  Currently, she is the Chair of the Medical and Scientific Advisory Board of the Long Island Alzheimer’s Foundation.

Professor, State University of New York

Nina R., Ph.D. is Professor of Psychiatry & Behavioral Sciences at SUNY Downstate Medical Center as well Adjunct Professor of Psychiatry at the Georgetown University School of Medicine, She also conducts research at the Veterans Affairs VISN 5 Mental Illness Research, Education and Clinical Center and The Zucker Hillside Hospital. She received her graduate training from Columbia University. Her current areas of research include long-term course of schizophrenia and its treatment, first episode schizophrenia and clinical trial design and management and clinical assessment.

Dr. Schooler is a fellow with the American College of Neuropsychopharmacology, fellow of the Collegium Internationale Neuropsychopharmacologicum, fellow of the American Psychological Association, snd fellow of the American Psychological Society. She ihas served as President of the American Psychopathological Association and the Association for Clinical Psychosocial Research. She is a recipient of the Gralnick Foundation High Point Hospital Award, the Alexander Gralnick Research Investigator Award and the Samuel Hamilton Award.

Director, Center for Outcomes and Evidence, Agency for Health Care Research and Quality

Jean Slutsky has directed the Center for Outcomes and Evidence (COE), Agency for Healthcare Research and Quality (AHRQ) of the U.S. Department of Health and Human Services since June 2003. Prior to Ms. Slutsky's appointment as director of COE, she served as acting director of the Center for Practice and Technology Assessment at AHRQ. Ms. Slutsky oversees the Evidence-based Practice Center program; Technology Assessment Program; extramural and intramural research portfolios concerning translating research into practice, outcomes and effectiveness research, including pharmaceutical outcomes, and cost-effectiveness analyses; and the National Guideline, Quality Measures, and QualityTools Clearinghouses.

Prior to becoming acting director of the Center for Practice and Technology Assessment, Ms. Slutsky directed the development of the National Guideline Clearinghouse™ (NGC) Project. The NGC is an Internet-based repository (www.guideline.gov) for comparative information on evidence-based clinical practice guidelines. In addition, Ms. Slutsky served as project director of the U.S. Preventive Services Task Force, an internationally recognized panel of experts who make evidence-based recommendations on clinical preventive services. Ms. Slutsky is a member of the Executive Board of the Guidelines International Network.

Ms. Slutsky received her Bachelor of Science degree at the University of Iowa, a Masters of Science in Public Health (Health Policy and Administration) from the University of North Carolina at Chapel Hill, and trained as a Physician Assistant at the University of Southern California.

Professor, Department of Health Policy and Management, Johns Hopkins University Bloomberg School of Public Health
Director of the Health Services Research and Development Center, Johns Hopkins University Bloomberg School of Public Health

Dr. Steinwachs' research seeks to identify opportunities to improve quality of health care and patient outcomes and when feasible, evaluate promising quality improvement interventions. His previous research includes studies of medical effectiveness and patient outcomes for individuals with specific medical (e.g., asthma), surgical (cataract surgery), and psychiatric (e.g., schizophrenia) conditions.

Dr. Steinwachs has contributed to the literature on the impact of managed care and payments systems on access to care, quality, utilization, and cost. He was a co-developer of the widely used ACG (Adjusted Clinical Groups) case mix adjustment. He has developed methods for measuring provider continuity, needs and unmet needs for care, and measures of the timeliness of care. He has a particular interest in the role of routine management information systems (MIS) as source of data for evaluating the effectiveness and cost of health care. This includes work on the integration of outcomes management systems with existing MIS in managed care settings.

Dr. Steinwachs was elected to the Institute of Medicine of the National Academy of Sciences in 1993, is past President of the Association for Health Services Research, and is an adviser to the Federal government, serving on the National Committee on Vital and Health Statistics.
Dr. Steinwachs holds a BS in Engineering Mathematics, a MS in Systems Engineering, from the University of Arizona and a Ph.D. in Operations Research from The Johns Hopkins University.

Professor of Biostatistics, University of Pennsylvania SOM

Dr. Ten Have's statistical research interests are in categorical data analysis, random effects models, informative dropout, treatment non-adherence, and designs and statistical analyses for complex adaptive treatment regimes. These methodological interests have contributed to the collaborative research projects on which Dr. Ten Have has served. Currently, Dr. Ten Have is Director of the Biostatistics-Data Core and Co-Investigator of the NIMH-sponsored Advanced Center for Intervention Services Research (ACISR) for Depression in the Aged. In this capacity, Dr. Ten Have is collaborating on trials involving the prevention of suicide in elderly primary care patient; the treatment of post-menopausal women with estrogen for depression; the treatment of substance abuse, anxiety, and depression in elderly veterans; and disparities of screening and treatment for mental health disorders in participants of color. He also is participating on a number of post-study analyses of disease-related functional disability and depression; the interaction of age and race on the association between estrogen or its precursors and depression; and the impact of hospitalization for delirium on elderly patients. In addition to investigating methods for accommodating drop-out in longitudinal studies, Dr. Ten Have is focusing on other methodological issues including: 1) accounting for different sources of non-adherence in randomized trials, such as patient- and physician-level non-adherence to randomized treatment regimes; 2) analyses of data from practice-randomized studies; and 3) designs and analyses of clinical trials investigating complex multi-component, adaptive treatment regimes. Finally, Dr. Ten Have is strongly committed to affirmative action in the recruitment of students, faculty members, investigators, study participants, and research topics.).

Dr. Ten Have is a member of the American Statistical Association, the Institute of Mathematical Statistics, the International Biometrics Society, the Society for Epidemiological Research, and the American Public Health Association. He is Associate Editor for Biometrics and Associate Editor for the Journal of the Royal Statistical Society, Series C.

Research Professor of Psychiatry, University of Texas at San Antonio
Associate Clinical Professor of Psychiatry, McLean Hospital, Harvard Medical School

Dr. Tohen received his medical degree from the National University of Mexico and his doctoral degree in Epidemiology from Harvard University. His postdoctoral training included a residency in Psychiatry at the University of Toronto, a clinical fellowship at McLean Hospital and Harvard Medical School, and a teaching fellowship in Epidemiology at the Harvard School of Public Health.

Dr. Tohen received a National Service Award in Psychiatric Epidemiology from the National Institute of Mental Health (NIMH) and Harvard University. He also received a FIRST award from NIMH, the Pope Award from McLean Hospital, and a NARSAD Young Investigator Award. He has served on the Epidemiology and Genetics and the Clinical Centers and Special Projects Review committees at NIMH.

Dr. Tohen has contributed more than 200 publications. He has co-edited 4 books, Psychiatric Epidemiology (1995 first edition, 2002 second edition), Mood Disorders Across the Life Span (1996), Bipolar Disorder: The Upswing in Research and Treatment (2005) and Bipolar Psychopharmacotherapy (2006). He also edited the book Comorbidity in Affective Disorders (1999).

Deputy Director, National Institute of Mental Health

Prior to joining NIMH, Dr. Wang served on the faculty at Harvard Medical School where his research focused on effectiveness trials, pharmacoepidemiology, pharmacoeconomics, and health services research. He completed his undergraduate, medical school, psychiatry residency, as well as doctoral training in epidemiology, all at Harvard University. Dr. Wang has served as a voting member on the FDA Psychopharmacologic Drugs Advisory Committee, FDA Neurological Devices Panel, and FDA Endocrinologic and Metabolic Drugs Advisory Committee. He also served on the NIMH Services Research and Clinical Epidemiology Study Section. He was Chair of the WHO World Mental Health Survey Services Research Work Group. He is a member of the American Psychiatric Association’s DSM-V Task Force and has consulted on several APA Work Groups to develop evidence-based treatment guidelines. Dr. Wang is an author of approximately 160 scientific publications.